920113-03-7

P276-00 is a cyclin-dependent kinase (CDK) inhibitor. P276-00 has shown to be highly selective for cancer cells and has shown to produce potent inhibition of Cdk4-D1 activity. P276-00 also induces apoptosis in human promyelocytic leukemia (HL-60) cells.

This cell cycle-inhibiting flavone and anticancer agent (FW = 438.30 g/mol; CAS 920113-03-7), also named 2- (2-chlorophenyl) -5,7-dihydroxy-8- [ (2R,3S) -2- (hydroxymethyl) -1-methyl-3-pyrrolidinyl]-4H-1-benzopyran-4- one, targets the Cyclin-Dependent Kinases CDK1 (IC50 = 79 nM), CDK4 (IC50 = 63 nM) and CDK9 (IC50 = 20 nM). p276-00 showed potent antiproliferative effects against various human cancer cell lines (IC50 values ranging from 300 to 800 nmol/L), but has little effect on cultured fibroblasts . A significant down-regulation of cyclin D1 and Cdk4 and a decrease in Cdk4-specific pRb Ser phosphorylation is observed. P276-00 produces potent inhibition of Cdk4-D1 activity that is competitive with ATP, and not with retinoblastoma protein. The compound also induced apoptosis in human promyelocytic leukemia (HL-60) cells, as evidenced by the induction of caspase-3 and DNA ladder studies. In 22 human cancer xenografts, P276-00 is approximately 26x more potent than cisplatin, and is also active against cisplatin-resistant tumors of central nervous system, melanoma, prostate, and renal cancers. Synchronized human non-small cell lung carcinoma (H-460) and human normal lung fibroblast (WI-38) cells are arrested in G1.

CDK9- Cyclin T1: 0.020 μM (IC₅₀); cdk4-cyclin D1: 0.063 μM (IC₅₀); CDK1-Cyclin B: 0.079 μM (IC₅₀); cdk2-cyclin A: 0.224 μM (IC₅₀); cdk2-cyclin E: 2.500 μM (IC₅₀); cdk6-cyclin D3: 0.396 μM (IC₅₀); CDK9-cyclin H: 2.900 μM (IC₅₀)

Store at -20° C